Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
V212-001 A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy	MSD	Completed	V212	3	V212-011	King Fahad Specialist Hospital (Dammam)
A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)	BioMarin Pharmaceutical Inc.	Completed	BMN 110	3	MOR-005	King Faisal Specialist Hospital and Research Center (Riyadh)
A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination	Roche	Completed	Bevacizumab	3	ML18147	King Fahad Specialist Hospital (Dammam), King Abdulaziz Hospital and Oncology Center (Jeddah), King Abdulaziz University Hospital (Jeddah), King Faisal Specialist Hospital and Research Center (Jeddah), King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/Week and 2.0 mg/kg/Every Other Week BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)	BioMarin Pharmaceutical Inc.	Completed	BMN 110	3	MOR-004	King Faisal Specialist Hospital and Research Center (Riyadh)
Multi-Center Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have An Inadequate Response to Current Non-Biologic DMARD or Anti-TNF Therapy	Roche	Completed	Tocilzumab	3b	MA21573	King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah), King Abdulaziz University Hospital (Jeddah)
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23 Valent pneumococcal polysacchride Vaccine.	Pfizer	Completed	13-valent Pneumoccocal Conjugate Vaccine	3	B1851013	King Faisal Specialist Hospital and Research Center (Riyadh)